The Role of Ribose in Patients Diagnosed With Fibromyalgia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-07-31

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purose of this research study is to determine the potential benefit of D-ribose, a nutritional supplement (a sugar), versus a placebo (another sugar) in people with fibromyalgia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Pilot Feasibility Study of Fibroblast Calcium and Glucoregulation in Health and Disease

NCT01917669

Type 2 Diabetes

WITHDRAWN

Effects of a Novel Supplement on Glycemic Variability Measured by Continuous Glucose Monitoring

NCT05832463

Healthy

COMPLETED NA

Study to Assess Safety and Effect of a Prebiotic Fiber Meal Replacement Shake in Individuals With Type 2 Diabetes

NCT05110703

Diabetes Mellitus, Type 2

COMPLETED NA

Blood Sugar Take Care and Glucose Metabolism

NCT01554020

Prediabetes

WITHDRAWN PHASE2

Resveratrol-Leucine Metabolite Synergy in Pre-diabetes

NCT01593605

Impaired Glucose Tolerance

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Two hundred to three hundred subjects (equally distribued between placebo and D-ribose) between 18-78 years of age will comprise this study. The final numbers enrolled will depend upon obtaining approximately 100 subjects that can display a high degree of compliance to TID dosing with approximately equal balance between the active and placebo arms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fibromyalgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

D-ribose 5 grams TID orally

Group Type ACTIVE_COMPARATOR

D-ribose

Intervention Type DIETARY_SUPPLEMENT

5 grams administered orally TID

2

Dextrose 5 grams TID

Group Type PLACEBO_COMPARATOR

dextrose

Intervention Type OTHER

5 grams orally TID

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

D-ribose

5 grams administered orally TID

Intervention Type DIETARY_SUPPLEMENT

dextrose

5 grams orally TID

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Corvalen

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* previous diagnosis of fibromomyalgia by a MD
* Has been diagnosed with fibromyalgia and are over 18 years of age
* Does live in the United States

Exclusion Criteria

* does NOT have severe medication/chemical/supplement sensitivities
* does NOT have insulin dependent diabetes or other severe illnesses (cancer, hepatitis, congestive heart failure)
* does NOT have rheumatoid arthritis or gout
* previous use of ribose

Minimum Eligible Age

18 Years

Maximum Eligible Age

78 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No